General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KWVUB
ADC Name
Thio-Tr (A121C)-BMPEO-DM1
Synonyms
Thio-Tr (A121C) BMPEO DM1
   Click to Show/Hide
Organization
Genentech, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
1.6
Antibody Name
Thio-Tr (A121C)
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
Maytansinoid DM1
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Thio-Tr (A121C)-BMPEO-DM1 linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Obtained from the Model Organism Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 83.69
%
Breast cancer model MMTV-HER2 Fo5
Tumor Growth Inhibition value (TGI) 
≈ 96.92
%
Breast cancer model MMTV-HER2 Fo5
Full List of Activity Data of This Antibody-drug Conjugate
Obtained from the Model Organism Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 83.69% (Day 7) High HER2 expression (HER2 +++)
Method Description
An allograft was propagated from the Fo5 mmty transgenic mouse which does not respond to.or responds poorly to HERCEPTIN therapy. Subjects were treated once with ADC (10 mg/kg); and placebo PBS buffer control (Vehicle) andmonitored over 3 weeks.
In Vivo Model Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 96.92% (Day 7) High HER2 expression (HER2 +++)
Method Description
An allograft was propagated from the Fo5 mmty transgenic mouse which does not respond to.or responds poorly to HERCEPTIN therapy. Subjects were treated once with ADC (21 mg/kg); and placebo PBS buffer control (Vehicle) andmonitored over 3 weeks.
In Vivo Model Breast cancer model MMTV-HER2 Fo5
References
Ref 1 Cysteine engineered antibodies and conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.